Articles & Research
from hVIVO

An introduction to participant recruitment in clinical trials

Participant recruitment in clinical trials is more than a formality; it plays a crucial role in the success of medical research. In this short guide, we explore what participant recruitment...

A New Era in Respiratory Vaccines: The modRNA Breakthrough and the Power of Human Challenge Trials

Executive Summary As respiratory vaccines continue to impose significant burdens on healthcare systems around the world, vaccine development has entered a transformative era. This white paper explores the history of...

hLAB Corporate Factsheet

A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a nonrandomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).

A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study

Safety, pharmacokinetics, and pharmacodynamics of AS-1763, a highly selective, orally bioavailable, non-covalent BTK inhibitor, in healthy volunteers (Abstract No. CT137)

Scientific Paper

Safety, pharmacokinetics, and pharmacodynamics of sofnobrutinib, a novel non-covalent BTK inhibitor, in healthy subjects: First-in-human phase I study

Human Challenge Trial Factsheet

hVIVO is an early phase full-service Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding...

Recruitment Factsheet

Stay connected

Sign up to our emails and follow us on social media to keep up to date with hVIVO.

By clicking Sign Up you're confirming that you agree with our Privacy Policy.